USP1 |
Improving DR outcomes |
Alleviating β-cell death, inhibiting VEGF-induced leakage |
(109, 127, 128) |
USP14 |
Leading to severer DR |
Activating inflammatory response through the TGF-β1 signal transduction, IκBα and NF-κB signaling pathway s in HG-treated Müller cells, as well as reactive oxygen species (ROS) |
(126) |
USPs and Diabetic Nephropathy |
Enzymes |
Function |
Mechanism |
References |
USP9X |
Protecting renal epithelial cells and alleviating DN |
Preventing EMT induced by HG in NRK-52E cells, downregulating TGF-β1 and FN |
(129, 130) |
USP14 |
Aggravating podocyte injury and DN |
Interacting with SPAG5-AS1 |
(131) |
USP15 |
Increasing HG-induced podocyte apoptosis, oxidative stress and inflammation |
Reducing the expression of Nrf2 target genes and Nrf2 activation in podocytes |
(132) |
USP22 |
Alleviating diabetic renal fibrosis, aggravating HG-induced apoptosis and inflammation in podocytes |
Activating Sirt1 signaling pathway |
(133–135) |
USP36 |
Aggravating DN |
Deubiquitinating DOCK4 and aggravating GEF-mediated EMT |
(136) |
USPs and Diabetic Neuropathic Pain |
Enzymes |
Function |
Mechanism |
References |
USP5 |
Affecting the DNP |
Interacting with Cav3.2 |
(137, 138) |
USP15 |
Alleviating DNP |
Promoting the ubiquitination and degradation of Nrf2, reducing the expression of G6PD |
(106, 137) |
USPs and Diabetic Foot |
Enzymes |
Function |
Mechanism |
References |
USP7 |
Slowing the progression of diabetic wound healing |
Upregulating in HUVECs and diabetic foot ulcers |
(107) |
USP30 |
Inhibiting wound healing in diabetic rats |
Activating NLRP3 inflammasomes by deubiquitinating NLRP3 |
(105) |
USPs and Diabetic Cardiomyopathy |
Enzymes |
Function |
Mechanism |
References |
USP8 |
Reducing blood glucose |
Interacting with Parkin |
(104) |
USP10 |
Reducing the risk of MI |
Deubiquitinating NICD1, modulating Notch signaling pathway |
(139) |